Milligan, G. (2010) The role of dimerisation in the cellular trafficking of G-protein-coupled receptors. Current Opinion in Pharmacology, 10(1), pp. 23-29. (doi: 10.1016/j.coph.2009.09.010) (PMID:19850521)

Ferre, S. et al. (2009) Building a new conceptual framework for receptor heteromers. Nature Chemical Biology, 5(3), pp. 131-134. (doi: 10.1038/nchembio0309-131)

Canals, M., Lopez-Gimenez, J. F. and Milligan, G. (2009) Cell surface delivery and structural re-organization by pharmacological chaperones of an oligomerization-defective α_1b-adrenoceptor mutant demonstrates membrane targeting of GPCR oligomers. Biochemical Journal, 417(1), pp. 161-172. (doi: 10.1042/BJ20081227)

Appelbe, S. and Milligan, G. (2009) Hetero‐Oligomerization of Chemokine Receptors. In: Chemokines, Part B. Series: Methods in Enzymology., 461. Academic Press, pp. 207-225. ISBN 9780123749079 (doi: 10.1016/S0076-6879(09)05410-X)

Lopez-Gimenez, J. F., Vilaro, M. T. and Milligan, G. (2008) Morphine desensitization, internalization and down-regulation of the μ opioid receptor is facilitated by serotonin 5-hydroxytryptamine_2A receptor co-activation. Molecular Pharmacology, 74(5), pp. 1278-1291. (doi: 10.1124/mol.108.048272) (PMID:18703670)

Xu, T.-R., Baillie, G. S. , Bhari, N., Houslay, T. M., Pitt, A. M., Adams, D. R., Kolch, W., Houslay, M. D. and Milligan, G. (2008) Mutations of β-arrestin 2 that limit self-association also interfere with interactions with the β₂-adrenoceptor and the ERK1/2 MAPKs: implications for β₂-adrenoceptor signalling via the ERK1/2 MAPKs. Biochemical Journal, 413(1), pp. 51-60. (doi: 10.1042/BJ20080685)

Canals Buj, M. and Milligan, G. (2008) Constitutive activity of the cannabinoid CB1 receptor regulates the function of co-expressed Mu opioid receptors. Journal of Biological Chemistry, 283(17), pp. 11424-11434. (doi: 10.1074/jbc.M710300200)

González-Maeso, J. et al. (2008) Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature, 452(7183), pp. 93-97. (doi: 10.1038/nature06612)

Milligan, G. (2008) A day in the life of a G protein-coupled receptor: the contribution to function of G protein-coupled receptor dimerization. British Journal of Pharmacology, 153(.), S216-S229. (doi: 10.1038/sj.bjp.0707490)

Milligan, G. (2007) G protein-coupled receptor dimerisation: molecular basis and relevance to function. Biochimica et Biophysica Acta: Biomembranes, 1768(4), pp. 825-835. (doi: 10.1016/j.bbamem.2006.09.021)

Lopez-Gimenez, J. F., Canals Buj, M., Pediani, J. D. and Milligan, G. (2007) The 1b-adrenoceptor exists as a higher-order oligomer: effective oligomerization is required for receptor maturation, surface delivery, and function. Molecular Pharmacology, 71(4), pp. 1015-1029. (doi: 10.1124/mol.106.033035)

Pin, J.P. et al. (2007) International union of basic and clinical pharmacology. LXVII. Recommendations for the recognition and nomenclature of g protein-coupled receptor heteromultimers. Pharmacological Reviews, 59(1), pp. 5-13. (doi: 10.1124/pr.59.1.5)

Milligan, G. (2007) Allosteric modulation of heterodimeric G-protein-coupled receptors. Trends in Pharmacological Sciences, 28(12), pp. 615-620. (doi: 10.1016/j.tips.2007.11.001)

Ellis, J., Pediani, J.D. , Canals Buj, M., Milasta, S. and Milligan, G. (2006) Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. Journal of Biological Chemistry, 281(25), pp. 38812-38824. (doi: 10.1074/jbc.M602494200)

Milligan, G. (2006) G-protein-coupled receptor heterodimers: pharmacology, function and relevance to drug discovery. Drug Discovery Today, 11, pp. 541-549. (doi: 10.1016/j.drudis.2006.04.007)